Abstract
Parkinson’s disease (PD) and schizophrenia (SZ) are two CNS disorders in which dysfunctions in the dopaminergic system and mitochondria are major pathologies. The symptomology of both, PD a neurodegenerative disorder and SZ a neurodevelopmental disorder, is completely different. However, the pharmacological treatment of each of the diseases can cause a shift of symptoms into those characteristic of the other disease. In this review, I describe a pathological interaction between dopamine and mitochondria in both disorders, which due to differences in the extent of oxidative stress leads either to cell death and tissue degeneration as in PD substantia nigra pars compacta or to distorted neuronal activity, imbalanced neuronal circuitry and abnormal behavior and cognition in SZ. This review is in the honor of Moussa Youdim who introduced me to the secrets of research work. His enthusiasm, curiosity and novelty-seeking inspired me throughout my career. Thank you Moussa.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Arakawa R, Ichimiya T, Ito H et al (2009) Increase in thalamic binding of [(11)C]PE2I in patients with schizophrenia: a positron emission tomography study of dopamine transporter. J Psychiatr Res 43:1219–1223. https://doi.org/10.1016/j.jpsychires.2009.04.009
Artiges E, Leroy C, Dubol M et al (2017) Striatal and extrastriatal dopamine transporter availability in schizophrenia and its clinical correlates: a voxel-based and high-resolution PET study. Schizophr Bull 43:1134–1142. https://doi.org/10.1093/schbul/sbw192
Association AP (1994) Diagnostic and statistical manual on mental disorders, fourth edition (DSM-IV)
Barrientos A, Moraes CT (1999) Titrating the effects of mitochondrial complex I impairment in the cell physiology. J Biol Chem 274:16188–16197
Basu B, Desai R, Balaji J et al (2008) Serotonin in pre-implantation mouse embryos is localized to the mitochondria and can modulate mitochondrial potential. Reproduction 135:657–669. https://doi.org/10.1530/REP-07-0577
Ben-Shachar D (2002) Mitochondrial dysfunction in schizophrenia: a possible linkage to dopamine. J Neurochem 83:1241–1251. https://doi.org/10.1046/j.1471-4159.2002.01263.x
Ben-Shachar D (2017) Mitochondrial multifaceted dysfunction in schizophrenia; complex I as a possible pathological target. Schizophr Res 187:3–10. https://doi.org/10.1016/j.schres.2016.10.022
Ben-Shachar D, Ene HMHM (2018) Mitochondrial targeted therapies: where do we stand in mental disorders? Biol Psychiatry 83:770–779. https://doi.org/10.1016/j.biopsych.2017.08.007
Ben-Shachar D, Karry R (2007) Sp1 expression is disrupted in schizophrenia; a possible mechanism for the abnormal expression of mitochondrial complex I genes, NDUFV1 and NDUFV2. PLoS One 2:e817
Ben-Shachar D, Karry R (2008) Neuroanatomical pattern of mitochondrial complex I pathology varies between schizophrenia, bipolar disorder and major depression. PLoS One 3:e3676
Ben-Shachar D, Laifenfeld D (2003) Mitochondria, synaptic plasticity, and schizophrenia
Ben-Shachar D, Youdim MBHB (1993) Iron, melanin and dopamine interaction: relevance to Parkinson’s disease. Prog Neuropsychopharmacol Biol Psychiatry 17:139–150. https://doi.org/10.1016/0278-5846(93)90038-T
Ben-Shachar D, Riederer P, Youdim MB (1991) Iron-melanin interaction and lipid peroxidation: implications for Parkinson’s disease. J Neurochem 57:1609–1614. https://doi.org/10.1111/j.1471-4159.1991.tb06358.x
Ben-Shachar D, Zuk R, Glinka Y (1995) Dopamine neurotoxicity: inhibition of mitochondrial respiration. J Neurochem 64:718–723. https://doi.org/10.1046/j.1471-4159.1995.64020718.x
Ben-Shachar D, Zuk R, Gazawi H et al (1999) Increased mitochondrial complex I activity in platelets of schizophrenic patients. Inter J Neuropsychopharmacol 2:245–253. https://doi.org/10.1017/S1461145799001649
Ben-Shachar D, Zuk R, Gazawi H, Ljubuncic P (2004) Dopamine toxicity involves mitochondrial complex I inhibition: implications to dopamine-related neuropsychiatric disorders. Biochem Pharmacol 67:1965–1974. https://doi.org/10.1016/j.bcp.2004.02.015
Bergman O, Ben-Shachar D (2016) Mitochondrial oxidative phosphorylation system (OXPHOS) deficits in schizophrenia: possible interactions with cellular processes. Can J Psychiatry 61:457–469. https://doi.org/10.1177/0706743716648290
Bergman O, Karry R, Milhem J, Ben-Shachar D (2018) NDUFV2 pseudogene (NDUFV2P1) contributes to mitochondrial complex I deficits in schizophrenia. Mol Psychiatry. https://doi.org/10.1038/s41380-018-0309-9
Berke JD (2018) What does dopamine mean? Nat Neurosci 21:787–793. https://doi.org/10.1038/s41593-018-0152-y
Biosa A, Arduini I, Soriano ME et al (2018) Dopamine oxidation products as mitochondrial endotoxins, a potential molecular mechanism for preferential neurodegeneration in Parkinson’s disease. ACS Chem Neurosci 9:2849–2858. https://doi.org/10.1021/acschemneuro.8b00276
Blesa J, Trigo-Damas I, Quiroga-Varela A, Jackson-Lewis VR (2015) Oxidative stress and Parkinson’s disease. Front Neuroanat. https://doi.org/10.3389/fnana.2015.00091
Bleuler M (1963) Conception of schizophrenia within the last fifty years and today [Abridged]. Proc R Soc Med 56:945–952. https://doi.org/10.1177/003591576305601048
Boengler K, Heusch G, Schulz R (2011) Nuclear-encoded mitochondrial proteins and their role in cardioprotection
Brenner-Lavie H, Klein E, Zuk R et al (2008) Dopamine modulates mitochondrial function in viable SH-SY5Y cells possibly via its interaction with complex I: relevance to dopamine pathology in schizophrenia. Biochim Biophys Acta 1777:173–185. https://doi.org/10.1016/j.bbabio.2007.10.006
Brenner-Lavie H, Klein E, Ben-Shachar D (2009) Mitochondrial complex I as a novel target for intraneuronal DA: modulation of respiration in intact cells. Biochem Pharmacol 78:85–95. https://doi.org/10.1016/j.bcp.2009.03.024
Burbulla LF, Song P, Mazzulli JR et al (2017a) Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson’s disease. Science (80-) 357:1255–1261. https://doi.org/10.1126/science.aam9080
Burbulla LF, Song P, Mazzulli JR et al (2017b) Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson’s disease. Science 357:1255–1261. https://doi.org/10.1126/science.aam9080
Callaly E, Walder K, Morris G et al (2015) Mitochondrial dysfunction in the pathophysiology of bipolar disorder: effects of pharmacotherapy. Mini Rev Med Chem 15:355–365
Calvo SE, Mootha VK (2010) The mitochondrial proteome and human disease. Annu Rev Genomics Hum Genet 11:25–44. https://doi.org/10.1146/annurev-genom-082509-141720
Cardoso MS (2011) The mitochondrial cascade hypothesis for parkinsons disease. Curr Pharm Des. https://doi.org/10.2174/138161211798072508
Chan T, Chow AM, Cheng XR et al (2012) Oxidative stress effect of dopamine on α-synuclein: electroanalysis of solvent interactions. ACS Chem Neurosci 3:569–574. https://doi.org/10.1021/cn300034t
Chandel NS (2015) Evolution of mitochondria as signaling organelles. Cell Metab 22:204–206
Chen D, Wilkinson CRM, Watt S et al (2008) Multiple pathways differentially regulate global oxidative stress responses in fission yeast. Mol Biol Cell 19:308–317. https://doi.org/10.1091/mbc.E07
Chouinard V-A, Kim S-Y, Valeri L et al (2017) Brain bioenergetics and redox state measured by 31P magnetic resonance spectroscopy in unaffected siblings of patients with psychotic disorders. Schizophr Res 187:11–16. https://doi.org/10.1016/j.schres.2017.02.024
Damier P, Hirsch EC, Agid Y, Graybiel AM (1999) The substantia nigra of the human brain: II. Patterns of loss of dopamine-containing neurons in Parkinson’s disease. Brain. https://doi.org/10.1093/brain/122.8.1437
Davis KL, Stewart DG, Friedman JI et al (2003) White matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch Gen Psychiatry 60:443–456
Dexter DT, Wells FR, Agid F et al (1987) Increased nigral iron content in postmortem parkinsonian brain. Lancet (London, England) 2:1219–1220. https://doi.org/10.1016/s0140-6736(87)91361-4
Dexter DT, Wells FR, Lee AJ et al (1989) Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson’s disease. J Neurochem. https://doi.org/10.1111/j.1471-4159.1989.tb07264.x
Dias V, Junn E, Mouradian MM (2013) The role of oxidative stress in parkinson’s disease. J Parkinsons, Dis
Dodson MW, Guo M (2007) Pink1, Parkin, DJ-1 and mitochondrial dysfunction in Parkinson’s disease. Curr Opin Neurobiol 17:331–337. https://doi.org/10.1016/j.conb.2007.04.010
Dror N, Klein E, Karry R et al (2002) State dependent alterations in mitochondrial complex I activity in platelets: a potential peripheral marker for schizophrenia. Mol Psychiatry 7:995–1001. https://doi.org/10.1038/sj.mp.4001116
Du F, Cooper AJ, Thida T et al (2014) In vivo evidence for cerebral bioenergetic abnormalities in schizophrenia measured using 31P magnetization transfer spectroscopy. JAMA Psychiatry 71:19–27. https://doi.org/10.1001/jamapsychiatry.2013.2287
Du J, Zhu M, Bao H et al (2016) The role of nutrients in protecting mitochondrial function and neurotransmitter signaling: implications for the treatment of depression, PTSD, and suicidal behaviors. Crit Rev Food Sci Nutr 56:2560–2578. https://doi.org/10.1080/10408398.2013.876960
Du F, Yuksel C, Chouinard V-A et al (2017) Abnormalities in high-energy phosphate metabolism in first-episode bipolar disorder measured using 31P-magnetic resonance spectroscopy. Biol Psychiatry. https://doi.org/10.1016/j.biopsych.2017.03.025
Fujimoto T, Nakano T, Takano T et al (1992) Study of chronic schizophrenics using 31P magnetic resonance chemical shift imaging. Acta Psychiatr Scand 86:455–462. https://doi.org/10.1111/j.1600-0447.1992.tb03297.x
Fusar-Poli P, Howes OD, Allen P et al (2011) Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis. Mol Psychiatry 16:67–75. https://doi.org/10.1038/mp.2009.108
Gazit N, Vertkin I, Shapira I et al (2016) IGF-1 receptor differentially regulates spontaneous and evoked transmission via mitochondria at hippocampal synapses. Neuron 89:583–597. https://doi.org/10.1016/j.neuron.2015.12.034
Gerlach M, Double K, Riederer P et al (1997) Iron in the Parkinsonian substantia nigra. Mov Disord 12:258–260
Gerlach M, Double KL, Ben-Shachar D et al (2003) Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson’s disease. Neurotox Res 5:35–44. https://doi.org/10.1007/bf03033371
Gibb WRG, Lees AJ (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry
Goold CP, Nicoll RA (2010) Single-cell optogenetic excitation drives homeostatic synaptic depression. Neuron 68:512–528. https://doi.org/10.1016/j.neuron.2010.09.020
Gu M, Owen AD, Toffa SE et al (1998) Mitochondrial function, GSH and iron in neurodegeneration and Lewy body diseases. J Neurol Sci 158:24–29. https://doi.org/10.1016/s0022-510x(98)00095-1
Haghighatfard A, Andalib S, Amini Faskhodi M et al (2018) Gene expression study of mitochondrial complex I in schizophrenia and paranoid personality disorder. World J Biol Psychiatry 19:S133–S146. https://doi.org/10.1080/15622975.2017.1282171
Harrington KA, Augood SJ, Kingsbury AE et al (1996) Dopamine transporter (Dat) and synaptic vesicle amine transporter (VMAT2) gene expression in the substantia nigra of control and Parkinson’s disease. Brain Res Mol Brain Res 36:157–162. https://doi.org/10.1016/0169-328x(95)00278-z
Hastings TG, Lewis DA, Zigmond MJ (1996) Reactive dopamine metabolites and neurotoxicity: implications for Parkinson’s disease. Adv Exp Med Biol 387:97–106. https://doi.org/10.1007/978-1-4757-9480-9_13
Hattoria N, Wanga M, Taka H et al (2009) Toxic effects of dopamine metabolism in Parkinson’s disease. Parkinsonism Relat Disord 15(Suppl 1):S35–S38. https://doi.org/10.1016/S1353-8020(09)70010-0
Hauser DN, Hastings TG (2013) Mitochondrial dysfunction and oxidative stress in Parkinson’s disease and monogenic parkinsonism. Neurobiol Dis 51:35–42. https://doi.org/10.1016/j.nbd.2012.10.011
Holper L, Ben-Shachar D, Mann JJ (2019) Multivariate meta-analyses of mitochondrial complex I and IV in major depressive disorder, bipolar disorder, schizophrenia, Alzheimer disease, and Parkinson disease. Neuropsychopharmacology 44:837–849. https://doi.org/10.1038/s41386-018-0090-0
Howes OD, Kapur S (2009) The dopamine hypothesis of schizophrenia: version III—the final common pathway. Schizophr Bull 35:549–562. https://doi.org/10.1093/schbul/sbp006
Howes OD, Kambeitz J, Kim E et al (2012) The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry 69:776–786. https://doi.org/10.1001/archgenpsychiatry.2012.169
Howes OD, McCutcheon R, Owen MJ, Murray RM (2017) The role of genes, stress, and dopamine in the development of schizophrenia. Biol Psychiatry 81:9–20. https://doi.org/10.1016/j.biopsych.2016.07.014
Huang ML-H, Lane DJR, Richardson DR (2011) Mitochondrial mayhem: the mitochondrion as a modulator of iron metabolism and its role in disease. Antioxid Redox Signal 15:3003–3019. https://doi.org/10.1089/ars.2011.3921
Hüttemann M, Helling S, Sanderson TH et al (2012) Regulation of mitochondrial respiration and apoptosis through cell signaling: cytochrome c oxidase and cytochrome c in ischemia/reperfusion injury and inflammation. Biochim Biophys Acta Bioenerg 1817:598–609. https://doi.org/10.1016/j.bbabio.2011.07.001
Ibata K, Sun Q, Turrigiano GG (2008) Rapid synaptic scaling induced by changes in postsynaptic firing. Neuron 57:819–826. https://doi.org/10.1016/j.neuron.2008.02.031
Iwamoto K, Bundo M, Kato T (2005) Altered expression of mitochondria-related genes in postmortem brains of patients with bipolar disorder or schizophrenia, as revealed by large-scale DNA microarray analysis. Hum Mol Genet 14:241–253. https://doi.org/10.1093/hmg/ddi022
Kambeitz J, Abi-Dargham A, Kapur S, Howes OD (2014) Alterations in cortical and extrastriatal subcortical dopamine function in schizophrenia: systematic review and meta-analysis of imaging studies. Br J Psychiatry 204:420–429. https://doi.org/10.1192/bjp.bp.113.132308
Kato T, Shioiri T, Murashita J et al (1995) Lateralized abnormality of high-energy phosphate and bilateral reduction of phosphomonoester measured by phosphorus-31 magnetic resonance spectroscopy of the frontal lobes in schizophrenia. Psychiatry Res 61:151–160. https://doi.org/10.1016/0925-4927(95)02752-j
Kirkbride JB, Errazuriz A, Croudace TJ et al (2012) Incidence of schizophrenia and other psychoses in England, 1950–2009: a systematic review and meta-analyses. PLoS One 7:e31660. https://doi.org/10.1371/journal.pone.0031660
Kroemer G, Blomgren K (2007) Mitochondrial cell death control in familial Parkinson disease. PLoS Biol. https://doi.org/10.1371/journal.pbio.0050206
Kudin AP, Malinska D, Kunz WS (2008) Sites of generation of reactive oxygen species in homogenates of brain tissue determined with the use of respiratory substrates and inhibitors. Biochim Biophys Acta 1777:689–695. https://doi.org/10.1016/j.bbabio.2008.05.010
Kuo SS, Pogue-Geile MF (2019) Variation in fourteen brain structure volumes in schizophrenia: a comprehensive meta-analysis of 246 studies. Neurosci Biobehav Rev 98:85–94. https://doi.org/10.1016/j.neubiorev.2018.12.030
Lakshminarayanan R, Madhavi S, Sim CPC (2018) Oxidative polymerization of dopamine: a high-definition multifunctional coatings for electrospun nanofibers—an overview. In: Dopamine—health and disease. InTech
Langston JW, Ballard P, Tetrud JW, Irwin I (2006) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science (80-) 219:979–980. https://doi.org/10.1126/science.6823561
Lebouvier T, Chaumette T, Paillusson S, et al (2009) The second brain and Parkinson’s disease. Eur J Neurosci
Leem J, Koh EH (2012) Interaction between mitochondria and the endoplasmic reticulum: implications for the pathogenesis of type 2 diabetes mellitus. Exp Diabetes Res 2012:1–8. https://doi.org/10.1155/2012/242984
Li Z, Okamoto K-II, Hayashi Y, Sheng M (2004) The importance of dendritic mitochondria in the morphogenesis and plasticity of spines and synapses. Cell 119:873–887. https://doi.org/10.1016/j.cell.2004.11.003
Lieberman JA (1999) Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol Psychiatry 46:729–739. https://doi.org/10.1016/S0006-3223(99)00147-X
Lopez MF, Kristal BS, Chernokalskaya E et al (2000) High-throughput profiling of the mitochondrial proteome using affinity fractionation and automation. In: Electrophoresis. pp 3427–3440
MacDonald ML, Garver M, Newman J et al (2019) Synaptic proteome alterations in the primary auditory cortex of individuals with schizophrenia. JAMA Psychiatry. https://doi.org/10.1001/jamapsychiatry.2019.2974
Mann VM, Cooper JM, Krige D et al (1992) Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson’s disease. Brain 115(Pt 2):333–342. https://doi.org/10.1093/brain/115.2.333
Maurer I, Zierz S, Moller H, Möller H-J (2001) Evidence for a mitochondrial oxidative phosphorylation defect in brains from patients with schizophrenia. Schizophr Res 48:125–136. https://doi.org/10.1016/S0920-9964(00)00075-X
Mazzulli JR, Xu Y-H, Sun Y et al (2011) Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146:37–52. https://doi.org/10.1016/j.cell.2011.06.001
McBride HM, Neuspiel M, Wasiak S (2006) Mitochondria: more than just a powerhouse. Curr Biol 16:R551–R560. https://doi.org/10.1016/j.cub.2006.06.054
McGlashan TH (1988) A selective review of recent North American long-term follow-up studies of schizophrenia. Schizophr Bull 14:515–542
McGlashan TH, Fenton WS (1992) The positive/negative distinction in schizophrenia: review of natural history validators. Arch Gen Psychiatry 49:63–72
McGlashan TH, Hoffman RE (2000) Schizophrenia as a disorder of developmentally reduced synaptic connectivity. Arch Gen Psychiatry 57:637–648
Middleton FA, Mirnics K, Pierri JN et al (2002) Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia. J Neurosci 22:2718–2729
Mizuno Y, Saitoh T, Sone N (1987) Inhibition of mitochondrial NADH-ubiquinone oxidoreductase activity by 1-methyl-4-phenylpyridinium ion. Biochem Biophys Res Commun 143:294–299
Mizuno Y, Suzuki K, Ohta S et al (1990) Postmortem changes in mitochondrial respiratory enzymes in brain and a preliminary observation in Parkinson’s disease. J Neurol Sci 96:49–57
Mongan D, Ramesar M, Föcking M et al (2019) Role of inflammation in the pathogenesis of schizophrenia: a review of the evidence, proposed mechanisms and implications for treatment. Early Interv Psychiatry. https://doi.org/10.1111/eip.12859
Nakaso K, Tajima N, Ito S et al (2013) Dopamine-mediated oxidation of methionine 127 in α-synuclein causes cytotoxicity and oligomerization of α-synuclein. PLoS One 8:e55068. https://doi.org/10.1371/journal.pone.0055068
Narendra D, Walker JE, Youle R (2012) Mitochondrial quality control mediated by PINK1 and Parkin: links to Parkinsonism. Cold Spring Harb. Perspect, Biol
Nicklas WM, Do J, Vyas I, Heikkila RE (1985) Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci 36:2503–2508. https://doi.org/10.1016/0024-3205(85)90146-8
Orth M, Schapira AHV (2001) Mitochondria and degenerative disorders. Am J Med Genet 106:27–36. https://doi.org/10.1002/ajmg.1425
Papa S, De Rasmo D, Technikova-Dobrova Z et al (2012) Respiratory chain complex I, a main regulatory target of the cAMP/PKA pathway is defective in different human diseases. FEBS Lett 586:568–577. https://doi.org/10.1016/j.febslet.2011.09.019
Parker WD, Parks JK, Swerdlow RH (2008) Complex I deficiency in Parkinson’s disease frontal cortex. Brain Res 1189:215–218. https://doi.org/10.1016/j.brainres.2007.10.061
Picard M, Wallace DC, Burelle Y (2016) The rise of mitochondria in medicine. Mitochondrion 30:105–116. https://doi.org/10.1016/j.mito.2016.07.003
Polymeropoulos MH, Lavedan C, Leroy E et al (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 276:2045–2047. https://doi.org/10.1126/science.276.5321.2045
Prabakaran S, Swatton JE, Ryan MM et al (2004) Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry 9:684–697. https://doi.org/10.1038/sj.mp.4001511
Premkumar A, Simantov R (2002) Mitochondrial voltage-dependent anion channel is involved in dopamine-induced apoptosis. J Neurochem 82:345–352. https://doi.org/10.1046/j.1471-4159.2002.00966.x
Riederer P, Sofic E, Rausch WD et al (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52:515–520. https://doi.org/10.1111/j.1471-4159.1989.tb09150.x
Robicsek O, Karry R, Petit I et al (2013) Abnormal neuronal differentiation and mitochondrial dysfunction in hair follicle-derived induced pluripotent stem cells of schizophrenia patients. Mol Psychiatry 18:1067–1076. https://doi.org/10.1038/mp.2013.67
Robicsek O, Ene HMHM, Karry R et al (2018) Isolated mitochondria transfer improves neuronal differentiation of schizophrenia-derived induced pluripotent stem cells and rescues deficits in a rat model of the disorder. Schizophr Bull 44:432–442. https://doi.org/10.1093/schbul/sbx077
Rodriguez-Oroz MC, Jahanshahi M, Krack P et al (2009) Initial clinical manifestations of Parkinson’s disease: features and pathophysiological mechanisms. Lancet Neurol
Rogalinska M (2016) The role of mitochondria in cancer induction, progression and changes in metabolism. Mini Rev Med Chem 16:524–30. https://doi.org/10.13140/RG.2.1.1996.6961
Rollins BL, Morgan L, Hjelm BE et al (2017) Mitochondrial complex I deficiency in schizophrenia and bipolar disorder and medication influence. Mol Neuropsychiatry 3:157–169. https://doi.org/10.1159/000484348
Rosenfeld M, Brenner-Lavie H, Ari SG-BGB, et al (2011) Perturbation in mitochondrial network dynamics and in complex I dependent cellular respiration in schizophrenia. Biol Psychiatry 69:980–988. https://doi.org/10.1016/j.biopsych.2011.01.010
Rund BR (2009) Is schizophrenia a neurodegenerative disorder? Nord J Psychiatry 63:196–201. https://doi.org/10.1080/08039480902767286
Schapira AH (1993) Mitochondrial complex I deficiency in Parkinson’s disease. Adv Neurol 60:288–291
Schilling B, Aggeler R, Schulenberg B et al (2005) Mass spectrometric identification of a novel phosphorylation site in subunit NDUFA10 of bovine mitochondrial complex I. FEBS Lett 579:2485–2490. https://doi.org/10.1016/j.febslet.2005.03.061
Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014) Biological insights from 108 schizophrenia-associated genetic loci. Nature 511:421–427. https://doi.org/10.1038/nature13595
Segura-Aguilar J, Paris I, Muñoz P et al (2014) Protective and toxic roles of dopamine in Parkinson’s disease. J Neurochem 129:898–915. https://doi.org/10.1111/jnc.12686
Shao L, Martin MV, Watson SJ et al (2008) Mitochondrial involvement in psychiatric disorders. Ann Med 40:281–295. https://doi.org/10.1080/07853890801923753
Sian J, Dexter DT, Lees AJ et al (1994) Glutathione-related enzymes in brain in Parkinson’s disease. Ann Neurol 36:356–361. https://doi.org/10.1002/ana.410360306
Smesny S, Rosburg T, Nenadic I et al (2007) Metabolic mapping using 2D 31P-MR spectroscopy reveals frontal and thalamic metabolic abnormalities in schizophrenia. Neuroimage 35:729–737. https://doi.org/10.1016/j.neuroimage.2006.12.023
Smeyne M, Smeyne RJ (2013) Glutathione metabolism and Parkinson’s disease. Free Radic Biol Med 62:13–25. https://doi.org/10.1016/j.freeradbiomed.2013.05.001
Sofic E, Riederer P, Heinsen H et al (1988) Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm 74:199–205. https://doi.org/10.1007/BF01244786
Sulzer D, Bogulavsky J, Larsen KE et al (2000) Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc Natl Acad Sci USA 97:11869–11874. https://doi.org/10.1073/pnas.97.22.11869
Telford JE, Kilbride SM, Davey GP (2009) Complex I is rate-limiting for oxygen consumption in the nerve terminal. J Biol Chem 284:9109–9114. https://doi.org/10.1074/jbc.M809101200
Thomas B, Beal MF (2007) Parkinson’s disease. Hum Mol Genet 16:R183–R194. https://doi.org/10.1093/hmg/ddm159
Vakifahmetoglu-Norberg H, Ouchida AT, Norberg E (2017) The role of mitochondria in metabolism and cell death. Biochem Biophys Res Commun 482:426–431. https://doi.org/10.1016/j.bbrc.2016.11.088
Valsecchi F, Ramos-Espiritu LS, Buck J et al (2013) cAMP and mitochondria. Physiology (Bethesda) 28:199–209. https://doi.org/10.1152/physiol.00004.2013
Valton V, Romaniuk L, Douglas Steele J et al (2017) Comprehensive review: computational modelling of schizophrenia. Neurosci Biobehav Rev 83:631–646. https://doi.org/10.1016/j.neubiorev.2017.08.022
van de Leemput J, Hess JL, Glatt SJ, Tsuang MT (2016) Genetics of schizophrenia: historical insights and prevailing evidence. Adv Genet 96:99–141. https://doi.org/10.1016/bs.adgen.2016.08.001
van den Heuvel MP, Fornito A (2014) Brain networks in schizophrenia. Neuropsychol Rev 24:32–48. https://doi.org/10.1007/s11065-014-9248-7
van Os J, Rutten BP, Poulton R (2008) Gene-environment interactions in schizophrenia: review of epidemiological findings and future directions. Schizophr Bull 34:1066–1082. https://doi.org/10.1093/schbul/sbn117
Vatrál J, Boča R, Linert W (2015) Oxidation properties of dopamine at and near physiological conditions. Monatshefte für Chemie Chem Mon 146:1799–1805. https://doi.org/10.1007/s00706-015-1560-2
Verge B, Alonso Y, Valero J et al (2011) Mitochondrial DNA (mtDNA) and schizophrenia. Eur Psychiatry 26:45–56. https://doi.org/10.1016/j.eurpsy.2010.08.008
Volz HP, Rzanny R, Rössger G et al (1998) 31Phosphorus magnetic resonance spectroscopy of the dorsolateral prefrontal region in schizophrenics—a study including 50 patients and 36 controls. Biol Psychiatry 44:399–404. https://doi.org/10.1016/s0006-3223(98)00061-4
Volz HP, Riehemann S, Maurer I et al (2000) Reduced phosphodiesters and high-energy phosphates in the frontal lobe of schizophrenic patients: A31P chemical shift spectroscopic-imaging study. Biol Psychiatry. https://doi.org/10.1016/S0006-3223(00)00235-3
Vyas I, Heikkila RE, Nicklas WJ (1986) Studies on the Neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: inhibition of NAD-linked substrate oxidation by its metabolite, 1-methyl-4-phenylpyridinium. J Neurochem. https://doi.org/10.1111/j.1471-4159.1986.tb01768.x
Wang JY, Zhuang QQ, Zhu LB et al (2016) Meta-analysis of brain iron levels of Parkinson’s disease patients determined by postmortem and MRI measurements. Sci Rep. https://doi.org/10.1038/srep36669
Washizuka S, Iwamoto K, Kazuno AA et al (2004) Association of mitochondrial complex I subunit gene NDUFV2 at 18p11 with bipolar disorder in Japanese and the National Institute of Mental Health pedigrees. Biol Psychiatry 56:483–489. https://doi.org/10.1016/j.biopsych.2004.07.004
White RJ, Reynolds IJ (1996) Mitochondrial depolarization in glutamate-stimulated neurons: an early signal specific to excitotoxin exposure. J Neurosci 16:5688–5697
Wong YC, Krainc D (2017) α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies. Nat Med 23:1–13. https://doi.org/10.1038/nm.4269
Youle RJ, Narendra DP (2011) Mechanisms of mitophagy. Nat Rev Mol Cell Biol 12:9–14. https://doi.org/10.1038/nrm3028
Zecca L, Zucca FA, Wilms H, Sulzer D (2003) Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics. Trends Neurosci 26:578–580. https://doi.org/10.1016/j.tins.2003.08.009
Zecca L, Casella L, Albertini A et al (2008) Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson’s disease. J Neurochem 106:1866–1875. https://doi.org/10.1111/j.1471-4159.2008.05541.x
Zhang F, Dryhurst G (1993) oxidation chemistry of dopamine: possible insights into the age-dependent loss of dopaminergic nigrostriatal neurons. Bioorg Chem 21:392–410. https://doi.org/10.1006/bioo.1993.1033
Zhou ZD, Lim TM (2009) Dopamine (DA) induced irreversible proteasome inhibition via DA derived quinones. Free Radic Res 43:417–430. https://doi.org/10.1080/10715760902801533
Zolotukhin PV, Belanova AA, Prazdnova EV et al (2016) Mitochondria as a signaling hub and target for phenoptosis shutdown. Biochemistry (Mosc) 81:329–337. https://doi.org/10.1134/S0006297916040039
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Ben-Shachar, D. The bimodal mechanism of interaction between dopamine and mitochondria as reflected in Parkinson’s disease and in schizophrenia. J Neural Transm 127, 159–168 (2020). https://doi.org/10.1007/s00702-019-02120-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-019-02120-x